The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials
نویسندگان
چکیده
منابع مشابه
The risk-escalation model: a principled design strategy for early-phase trials.
Should first-in-human trials be designed to maximize the prospect of therapeutic benefit for volunteers, prioritize avoidance of unintended harms, or aim for some happy medium between the two? Perennial controversies surrounding initiation and design of early-phase trials hinge on how this question is resolved. In this paper, we build on the premise that the task of early-phase testing is to op...
متن کاملinvestigating the feasibility of a proposed model for geometric design of deployable arch structures
deployable scissor type structures are composed of the so-called scissor-like elements (sles), which are connected to each other at an intermediate point through a pivotal connection and allow them to be folded into a compact bundle for storage or transport. several sles are connected to each other in order to form units with regular polygonal plan views. the sides and radii of the polygons are...
Implementation Procedures for the Risk in Early Design (RED) Method
Risk assessments performed at the conceptual design phase of a product may offer the greatest opportunity to increase product safety and reliability at the least cost. This is an especially difficult proposition, however, as often the product has not assumed a physical form at this early design stage. This paper introduces the Risk in Early Design (RED) method, a method for performing risk asse...
متن کاملA product of independent beta probabilities dose escalation design for dual-agent phase I trials
Dual-agent trials are now increasingly common in oncology research, and many proposed dose-escalation designs are available in the statistical literature. Despite this, the translation from statistical design to practical application is slow, as has been highlighted in single-agent phase I trials, where a 3 + 3 rule-based design is often still used. To expedite this process, new dose-escalation...
متن کاملEscalation strategies for combination therapy Phase I trials
Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose that does not cause an unacceptable amount of toxicity in the patients. In trials of combination therapies, however, many different dose combinations may have a similar probability of causing a dose-limiting toxicity, and hence, a number of MTDs may exist. Furthermore, escalation strategies in comb...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kennedy Institute of Ethics Journal
سال: 2014
ISSN: 1086-3249
DOI: 10.1353/ken.2014.0017